Cipla’s first-quarter profit declined significantly, impacted by muted cancer drug sales. U.S. supply disruptions for a tumor treatment also affected the company’s financial results. The drugmaker appointed Dinesh Jain as its new global finance chief on Friday. Cipla’s India business showed strong double-digit growth in key therapy areas. North America revenue experienced a notable decrease during the reporting period.